Phaseline

Companies › Ankyra Therapeutics

Ankyra Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
tolododekin alfa (ANK-101)–Phase 1Advanced Solid Tumor; Non Small Cell Lung CancerApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06171750tolododekin alfa (ANK-101)Phase 1Advanced Solid TumorOncologyApr 2027
NCT07027514tolododekin alfa (ANK-101)Phase 1Non Small Cell Lung CancerOncologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.